JP Morgan Maintains Neutral Rating On Biogen Idec After Positive Phase 3 BG-12 Results
Biogen Announced Positive Phase 3 Results For BG-12, Deutsche Bank Maintains Hold
JP Morgan Maintains Neutral Rating On Biogen Idec After Positive Phase 3 BG-12 Results
Biogen Announced Positive Phase 3 Results For BG-12, Deutsche Bank Maintains Hold
Icahn Moves To Sell Biogen Idec (BIIB) After Adding another Director
Roche And Biogen Idec (BIIB) Suspend Rheumatoid Arthritis Drug Program